Department of Thoracic Medicine, St. Olavs Hospital HF, Trondheim University Hospital, Trondheim, Norway.
J Thorac Oncol. 2011 Nov;6(11):1810-7. doi: 10.1097/JTO.0b013e31822a75be.
Patients with lung cancer have a high frequency of comorbidity. Data on the impact of diabetes mellitus, the most frequent endocrine disorder, on the prognosis of lung cancer are conflicting. The aim was to investigate the impact of diabetes mellitus on survival in lung cancer.
We analyzed data from a cohort, the Nord-Trøndelag Health Study (HUNT study) linked to the Norwegian Cancer Registry and controlled the results using two lung cancer studies, the Pemetrexed Gemcitabine study and the Norwegian Lung Cancer Biobank. Survival in lung cancer with and without diabetes mellitus was compared using the Kaplan-Meier method and Cox regression model for each study and the studies combined.
One thousand six hundred seventy-seven cases of lung cancer were included, 1031 from HUNT study, 436 from the Pemetrexed Gemcitabine study, and 210 from the Norwegian Lung Cancer Biobank registry, and among these 77 patients had diabetes mellitus. In the combined analysis, patients with lung cancer with diabetes mellitus had increased survival compared with those without (p = 0.005). The 1-, 2-, and 3-year survival in patients with lung cancer with and without diabetes mellitus were 43% versus 28%, 19% versus 11%, and 3% versus 1%, respectively. Adjusting for age, gender, histology, and stage of disease in the Cox regression model, the hazard ratio for survival in patients with lung cancer with diabetes mellitus was 0.55 (95% CI, 0.41-0.75) as compared with without.
Patients with lung cancer with diabetes mellitus have an increased survival compared with those without diabetes mellitus.
肺癌患者常合并多种疾病。糖尿病是最常见的内分泌疾病之一，其对肺癌预后的影响数据存在争议。本研究旨在探讨糖尿病对肺癌患者生存的影响。
我们分析了一个队列的资料，即诺尔兰健康研究（HUNT 研究），该研究与挪威癌症登记处相关联，并使用两个肺癌研究（培美曲塞联合吉西他滨研究和挪威肺癌生物库）对结果进行了控制。使用 Kaplan-Meier 方法和 Cox 回归模型比较了有和无糖尿病的肺癌患者的生存情况，每个研究和联合研究均进行了比较。
共纳入 1677 例肺癌病例，其中 1031 例来自 HUNT 研究，436 例来自培美曲塞联合吉西他滨研究，210 例来自挪威肺癌生物库登记处，其中 77 例患有糖尿病。在联合分析中，患有糖尿病的肺癌患者的生存时间长于无糖尿病的患者（p = 0.005）。有和无糖尿病的肺癌患者的 1、2 和 3 年生存率分别为 43%比 28%、19%比 11%和 3%比 1%。在 Cox 回归模型中调整年龄、性别、组织学和疾病分期后，患有糖尿病的肺癌患者的生存风险比为 0.55（95%CI，0.41-0.75）。
与无糖尿病的肺癌患者相比，患有糖尿病的肺癌患者的生存时间更长。
